Paroxysmal supraventricular tachycardia (PSVT), fractional flow reserve testing (diagnostic aid), narrow-complex regular tachycardia (unstable), pulmonary artery hypertension (acute vasodilator testing).

Antiarrhythmic Agent, Miscellaneous; Diagnostic Agent

Onset of action: Rapid.
Duration: Very brief.
Metabolism: Removed from systemic circulation primarily by vascular endothelial cells and erythrocytes (by cellular uptake); rapidly metabolized intracellularly.
Half-life elimination: <10 seconds.

Hypersensitivity to adenosine or any component of the formulation; second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia; known or suspected bronchoconstrictive or bronchospastic lung disease, asthma.

C

>10%: cardiac arrhythmia (55%), chest pressure (7% to 40%), headache (2% to 18%), dizziness (≤12%), facial flushing (18% to 44%), gastrointestinal distress (13%), neck discomfort (<1% to 15%), dyspnea (12% to 28%).

For rapid bolus intravenous (peripheral venous bolus dosing) use only.
Paroxysmal supraventricular tachycardia:
Initial dose: 6 mg given as a rapid intravenous bolus (administered over a 1-2 second period).
Repeat administration: If the first dose does not result in elimination of the supraventricular tachycardia within 1 to 2 minutes, 12 mg should be given as a rapid intravenous bolus. This 12 mg dose may be repeated a second time if required.

Supraventricular tachycardia (Hemodynamically stable):
Pediatric Patients with a Body Weight < 50 kg :
Initial dose: give 0.05 to 0.1 mg/kg as a rapid IV bolus given either centrally or peripherally. A saline flush should follow.
Repeat administration: If conversion of PSVT does not occur within 1-2 minutes, increasing the amount given by 0.05 to 0.1 mg/kg. Follow each bolus with a saline flush. Maximum single dose: 0.3 mg/kg.
Pediatric Patients with a Body Weight ≥ 50 kg: Administer the adult dose.